Methylcobalamin Injection Dosing
There is no established mg/kg dosing for methylcobalamin injections in standard clinical practice; instead, fixed-dose protocols are used based on the indication and patient age.
Standard Dosing from FDA-Approved Labeling
The FDA-approved cyanocobalamin (vitamin B12) injection provides the clearest guidance 1:
- Adults: 1000 mcg (1 mg) intramuscularly, typically monthly for maintenance in pernicious anemia
- Pediatric patients: 0.5 to 3 mcg daily (oral equivalent recommendations from Food and Nutrition Board)
- Pregnancy/Lactation: 4 mcg daily recommended intake
Important caveat: These are fixed doses, not weight-based calculations. The FDA label explicitly does not provide mg/kg dosing recommendations 1.
Emerging Research-Based Weight Dosing
Recent research studies have explored weight-based dosing in specific contexts:
Ultra-High Dose Protocols (Investigational)
For amyotrophic lateral sclerosis (ALS), research protocols used 50 mg intramuscularly twice weekly in adults 2. This represents approximately 0.7-1.0 mg/kg per dose for average-weight adults, but this is investigational and not approved for general use.
Pediatric Sublingual Protocol
A recent pediatric study used sublingual methylcobalamin (not injection) at 3:
- Children <8 years: 500 mcg daily
- Children ≥8 years: 1000 mcg daily
This translates to approximately 10-20 mcg/kg/day for younger children, though this was sublingual administration.
Animal Research Dosing
Preclinical studies used 4, 5:
- 10 mcg/kg intramuscularly in mice (tumor studies)
- 100 mg/kg intraperitoneally in mice (high-dose tumor suppression studies)
These animal doses cannot be directly extrapolated to humans.
Clinical Practice Recommendations
For vitamin B12 deficiency treatment in clinical practice:
- Do not use weight-based dosing - use fixed-dose protocols instead
- Standard treatment: 1000 mcg IM initially, then monthly maintenance 1
- Pediatric dosing: Follow age-appropriate fixed doses (0.5-3 mcg daily equivalent) rather than calculating per kilogram 1
Critical Safety Considerations
- Hypokalemia risk: Monitor serum potassium closely in the first 48 hours of treatment, especially in severe megaloblastic anemia 1
- Anaphylaxis: Consider intradermal test dose before administration in suspected sensitive patients 1
- Benzyl alcohol toxicity: Products containing benzyl alcohol are contraindicated in premature neonates due to "Gasping Syndrome" risk 1
- Aluminum toxicity: Prolonged parenteral administration poses risk, particularly in renal impairment and premature neonates 1
- Folic acid masking: Doses >0.1 mg/day folic acid may mask B12 deficiency while allowing irreversible neurologic damage to progress 1
Monitoring Requirements
- Baseline: Hematocrit, reticulocyte count, vitamin B12, folate, iron levels, serum potassium 1
- Days 5-7: Daily hematocrit and reticulocyte counts 1
- Ongoing: Frequent monitoring until hematocrit normalizes 1
The evidence does not support routine mg/kg dosing for methylcobalamin injections in standard clinical practice. Use established fixed-dose protocols based on indication and patient age rather than attempting weight-based calculations.